Pharmacokinetics, biliary excretion, and tissue distribution of novel anti-HIV agents, cosalane and dihydrocosalane, in Sprague-Dawley rats

Drug Metabolism and Disposition

Volumn 28, Issue 4, 2000, Pages 403-408

  Kuchimanchi, Kameswara R ^a   Udata, Chandrasekhar ^a   Johnston, Thomas P ^a   Mitra, Ashim K ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; COSALANE; DIHYDROCOSALANE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BILIARY EXCRETION; CONCENTRATION RESPONSE; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG STRUCTURE; ENTEROHEPATIC CIRCULATION; HUMAN IMMUNODEFICIENCY VIRUS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TISSUE DIFFERENTIATION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-HIV AGENTS; AURINTRICARBOXYLIC ACID; BILE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENTEROHEPATIC CIRCULATION; INJECTIONS, INTRAVENOUS; MALE; MODELS, BIOLOGICAL; RATS; RATS, SPRAGUE-DAWLEY; SPECTROPHOTOMETRY, ULTRAVIOLET; TISSUE DISTRIBUTION;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0034114537     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Bigelow J, Mathews L, Chrin L, Horton P and McCormack J (1994) Analytical studies and murine pharmacokinetics of cosalane. Proc Am Assn Cancer Res 35:427.
2. Chou C-H. McLachlan AJ and Rowland M (1995) Membrane permeability and lipophilicity in the isolated perfused rat liver: 5-Ethyl barbiluric acid and other compounds. J Pharmacol Exp Ther 275:933-940.
3. Colburn WA, Hirom PC, Parker RJ and Milburn P (1979) A pharmacokinetic model for enterohepatic recirculation in the rat: Phenolphthalein, a model drug. Drug Metab Dispos 7:100-102.
4. Cushman M, Golebiewski WM, McMohan JB, Buckheit RW Jr, Clanton DJ, Weislow O, Haugwitz RD, Bader JP, Graham L and Rice WG (1994) Design, synthesis and biological evaluation of cosalane, a novel anti-HIV agent which inhibits multiple features of virus reproduction. J Med Chem 37:3040-3050.
5. Cushman M, Golebiewski WM, Pommier Y, Mazumder A, Reymen D, De Clercq E, Graham L and Rice WG (1995) Cosalane analogues with enhanced potencies as inhibitors of HIV-I protease integrase. J Med Chem 38:443-452.
6. Eeckhoudt SL, Evard PA and Verbeeck RK (1997) Biliary excretion and enterohepatic cycling of R- and S-flurbiprofen in the rat. Drug Metab Dispos 25:428-430.
7. Gerlowski LE and Jain RK (1983) Physiologically based pharmacokinetic modeling: Principles and applications. J Pharm Sci 72:1103-1127.
8. Golebiewski WM, Bader JP and Cushman M (1993) Design and synthesis of cosalane, a novel anti-HIV agent. Bioorg Med Chem Lett 3:1739-1742.
9. Golebiewski WM, Keyes RF and Cushman M (1996) Exploration of the effects of linker chain modifications on anti-HIV activities in a series of cosalane analogues. Bioorg Med Chem 4:1637-1648.
10. Hirom PC, Millburn P, Smith RL and Williams RT (1972) Species variations in the threshold molecular-weight factor for the biliary excretion of organic anions. Biochem J 129:1071-1077.
11. Keyes RF, Golebiewski WM and Cushman M (1996) Correlation of anti-HIV potency with lipophilicity in a series of cosalane analogs having normal alkenyl and phosphodiester chains as cholestane replacements. J Med Chem 39:508-514.
12. Martin YC (1981) A practitioner's perspective of the role of quantitative structure-activity analysis in medicinal chemistry. J Med Chem 24:229-237.
13. Pal D, Udata C and Mitra AK (1998) Effect of protein binding and membrane partitioning on transcellular permeability of highly lipophilic novel anti-HIV agent cosalane across Caco-2 cell monolayers. Pham Sci Suppl 1:S93.
14. Pollack GM and Brouwer LR (1991) Physiologic and metabolic influences on enterohepatic recirculation: Simulations based upon the disposition of valproic acid in the rat. J Pharmcokinet Biopharm 19:189-225.
15. Rowland M and Evans AM (1991) Physiologic models of hepatic elimination, in new Trends in Pharmacokinetics (Rescigno A and Thakur AK) pp 83-102. Plenum Press, New York.
16. Rowland M and Tozer TN (1989) Movement through membranes, in Clinical Pharmacokinetics (Rowland M and Tozer TN eds.) pp 103-112, Lea & Febiger, Philadelphia.
17. Smith RL (1973) Factors affecting biliary excretion, in The Excretory Function of Bile (Smith RL ed) pp 16-34, Chapman and Hall, London.
18. Tomlinson PW, Jeffery DJ and Filer CW (1981) A novel technique for assessment of biliary secretion and enterohepatic circulation in the unrestrained conscious rat. Xenobiotica 11:863-870.
19. Udata C, Mitra AK and Badr MZ (1999) Disposition of cosalane in isolated perfused rat livers. Drug Metab Dispos 27:947-950.
20. Venkatesh S, Li J, Xu Y, Vishnuvajjala R and Anderson BD (1996) Intrinsic solubility estimation and pH-solubility behavior of cosalane (NSC 658586). an extremely hydrophobic diprotic acid. Pharm Res 13:1453-1459.
21. Wils P. Warnery A, Phung-ba V, Legrain S and Scherman D (1994) High lipophilicity decreases drug transport across intestinal epithelial cells. J Pharmacol Exp Ther 269:654-658.
22. Wisse E, De Zanger RB, Charels P. Van Der Smissen P and McCuskey RS (1985) The liver sieve: Considerations concerning the structure and function of endothelial fenestrae, the sinusoidal wall and the space of Disse. Hepatology 5:683-692.